South Korea · Delayed Price · Currency is KRW PanGen Biotech Statistics
Total Valuation
PanGen Biotech has a market cap or net worth of KRW 68.96 billion. The enterprise value is 56.11 billion.
| Market Cap | 68.96B |
| Enterprise Value | 56.11B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PanGen Biotech has 13.49 million shares outstanding. The number of shares has increased by 22.05% in one year.
| Current Share Class | 13.49M |
| Shares Outstanding | 13.49M |
| Shares Change (YoY) | +22.05% |
| Shares Change (QoQ) | -0.28% |
| Owned by Insiders (%) | 4.06% |
| Owned by Institutions (%) | n/a |
| Float | 6.37M |
Valuation Ratios
The trailing PE ratio is 35.00.
| PE Ratio | 35.00 |
| Forward PE | n/a |
| PS Ratio | 5.14 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 363.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.88, with an EV/FCF ratio of -150.44.
| EV / Earnings | 27.36 |
| EV / Sales | 4.18 |
| EV / EBITDA | 18.88 |
| EV / EBIT | 37.25 |
| EV / FCF | -150.44 |
Financial Position
The company has a current ratio of 8.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.43 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | -2.58 |
| Interest Coverage | 10.33 |
Financial Efficiency
Return on equity (ROE) is 7.48% and return on invested capital (ROIC) is 8.59%.
| Return on Equity (ROE) | 7.48% |
| Return on Assets (ROA) | 2.98% |
| Return on Invested Capital (ROIC) | 8.59% |
| Return on Capital Employed (ROCE) | 5.03% |
| Weighted Average Cost of Capital (WACC) | 3.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.35 |
Taxes
In the past 12 months, PanGen Biotech has paid 16.53 million in taxes.
| Income Tax | 16.53M |
| Effective Tax Rate | 0.80% |
Stock Price Statistics
The stock price has increased by +11.23% in the last 52 weeks. The beta is -0.19, so PanGen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.19 |
| 52-Week Price Change | +11.23% |
| 50-Day Moving Average | 5,184.30 |
| 200-Day Moving Average | 5,808.13 |
| Relative Strength Index (RSI) | 48.28 |
| Average Volume (20 Days) | 11,953 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PanGen Biotech had revenue of KRW 13.42 billion and earned 2.05 billion in profits. Earnings per share was 146.00.
| Revenue | 13.42B |
| Gross Profit | 4.50B |
| Operating Income | 1.51B |
| Pretax Income | 2.07B |
| Net Income | 2.05B |
| EBITDA | 2.97B |
| EBIT | 1.51B |
| Earnings Per Share (EPS) | 146.00 |
Balance Sheet
The company has 13.80 billion in cash and 962.44 million in debt, with a net cash position of 12.84 billion or 951.62 per share.
| Cash & Cash Equivalents | 13.80B |
| Total Debt | 962.44M |
| Net Cash | 12.84B |
| Net Cash Per Share | 951.62 |
| Equity (Book Value) | 29.92B |
| Book Value Per Share | 2,193.06 |
| Working Capital | 20.39B |
Cash Flow
In the last 12 months, operating cash flow was 189.81 million and capital expenditures -562.81 million, giving a free cash flow of -373.00 million.
| Operating Cash Flow | 189.81M |
| Capital Expenditures | -562.81M |
| Depreciation & Amortization | 1.47B |
| Net Borrowing | -1.84M |
| Free Cash Flow | -373.00M |
| FCF Per Share | -27.64 |
Margins
Gross margin is 33.52%, with operating and profit margins of 11.23% and 15.28%.
| Gross Margin | 33.52% |
| Operating Margin | 11.23% |
| Pretax Margin | 15.41% |
| Profit Margin | 15.28% |
| EBITDA Margin | 22.15% |
| EBIT Margin | 11.23% |
| FCF Margin | n/a |
Dividends & Yields
PanGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.05% |
| Shareholder Yield | -22.05% |
| Earnings Yield | 2.97% |
| FCF Yield | -0.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PanGen Biotech has an Altman Z-Score of 18.37 and a Piotroski F-Score of 4.
| Altman Z-Score | 18.37 |
| Piotroski F-Score | 4 |